Literature DB >> 35288737

Role of Prostaglandin E2 in the Progression of Gastrointestinal Cancer.

David Jay Wilson1, Raymond N DuBois2.   

Abstract

Chronic inflammation is a well-established risk factor for several diseases, including cancer. It influences tumor cell biology and the type and density of immune cells in the tumor microenvironment (TME), promoting cancer development. While proinflammatory cytokines and chemokines modulate cancer development, emerging evidence has shown that prostaglandin E2 (PGE2) is a known mediator connecting chronic inflammation to cancerization. This review highlights recent advances in our understanding of how the elevation of PGE2 production promotes gastrointestinal cancer initiation, progression, invasion, metastasis, and recurrence, including modulation of immune checkpoint signaling and the type and density of immune cells in the tumor/tissue microenvironment. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35288737      PMCID: PMC9359060          DOI: 10.1158/1940-6207.CAPR-22-0038

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  97 in total

1.  Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia.

Authors:  J Chad Johnson; Carl R Schmidt; Martha J Shrubsole; D Dean Billheimer; Prashant R Joshi; Jason D Morrow; Martin J Heslin; M Kay Washington; Reid M Ness; Wei Zheng; David A Schwartz; Robert J Coffey; R Daniel Beauchamp; Nipun B Merchant
Journal:  Clin Gastroenterol Hepatol       Date:  2006-09-25       Impact factor: 11.382

Review 2.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

3.  Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer.

Authors:  P Patrignani; A Sacco; C Sostres; A Bruno; M Dovizio; E Piazuelo; L Di Francesco; A Contursi; M Zucchelli; S Schiavone; S Tacconelli; C Patrono; A Lanas
Journal:  Clin Pharmacol Ther       Date:  2017-04-04       Impact factor: 6.875

Review 4.  The Tumor Microenvironment Innately Modulates Cancer Progression.

Authors:  Dominique C Hinshaw; Lalita A Shevde
Journal:  Cancer Res       Date:  2019-07-26       Impact factor: 12.701

5.  Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway.

Authors:  Hiroko Oshima; Akihiro Matsunaga; Takashi Fujimura; Tetsuya Tsukamoto; Makoto M Taketo; Masanobu Oshima
Journal:  Gastroenterology       Date:  2006-10       Impact factor: 22.682

6.  Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis.

Authors:  Nishanth Sivarasan; Geoff Smith
Journal:  J Dig Dis       Date:  2013-05       Impact factor: 2.325

7.  Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.

Authors:  Shuji Ogino; Gregory J Kirkner; Katsuhiko Nosho; Natsumi Irahara; Shoko Kure; Kaori Shima; Aditi Hazra; Andrew T Chan; Reiko Dehari; Edward L Giovannucci; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

8.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

9.  Prostaglandin E2 promotes intestinal tumor growth via DNA methylation.

Authors:  Dianren Xia; Dingzhi Wang; Sun-Hee Kim; Hiroshi Katoh; Raymond N DuBois
Journal:  Nat Med       Date:  2012-01-22       Impact factor: 53.440

Review 10.  Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways.

Authors:  Kanae Echizen; Osamu Hirose; Yusuke Maeda; Masanobu Oshima
Journal:  Cancer Sci       Date:  2016-03-18       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.